Patients were randomised to receive either formoterol (Oxis® Turbuhaler®; AstraZeneca, Lund, Sweden; 4.5 μg per delivered dose) or salbutamol (pressurised metered-dose inhaler [pMDI]/dry powder inhaler [DPI]; Diskhaler® [200 μg per dose; Ventolin™, GlaxoSmithKline, Uxbridge, UK], Diskus® [200 μg per dose; Ventolin™, GlaxoSmithKline, Uxbridge, UK] or Turbuhaler® [100 μg per dose; Inspiryl®, AstraZeneca, Lund, Sweden]), treatment was available to patients on the first day of the study immediately after randomization. Since these therapies were provided on an as-needed basis, compliance was not measured.
Diskhaler
Manufactured by GlaxoSmithKline
Sourced in United Kingdom, Sweden
The Diskhaler is a portable, hand-held device used for the delivery of inhalation medications. It is designed to hold and dispense pre-packaged medication disks, which contain individual doses of the medication. The Diskhaler provides a convenient and controlled method for patients to inhale their prescribed medication.
Automatically generated - may contain errors
2 protocols using diskhaler
1
Randomized Asthma Rescue Medication Trial
2
Inhaler Device Evaluation in Asthma
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A total of 568 adult subjects (276 male, 292 female) who were on inhaler therapy for at least one month were included in this cross-sectional, observational study conducted at a tertiary pneumology out-patient clinic between June 2017 and February 2018. pMDIs and several DPIs including Aerolizer (Novartis, Surrey, UK), Handihaler (Boehringer Ingelheim, Ingelheim, Germany), Turbuhaler (Astra, Lund, Sweden) and Diskhaler (GlaxoSmithKline, Ware, UK) were assessed in this study as the most commonly used devices of those available in Turkey. Subjects > 18 y old who were diagnosed with asthma according to the Asthma, COPD, and asthma-COPD overlap syndrome, GINA, and GOLD criteria were included in this study. 11 The use of inhaler therapy for less than one month, lack of attendance to regular control visits, confirmed or suspected pregnancy, breastfeeding, allergy, sensitivity or intolerance to asthma or COPD therapy, and being on nebulizer therapy were the exclusion criteria applied to this study.
Written informed consent was obtained from each subject following a detailed explanation of the study objectives and protocol. This study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital Ethics Committee.
Written informed consent was obtained from each subject following a detailed explanation of the study objectives and protocol. This study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital Ethics Committee.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!